Biomarkers and heart disease

Journal of Clinical Sleep Medicine

Volumn 7, Issue 5, 2011, Pages

  Albert, Michelle A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIURETIC AGENT; FLECAINIDE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; STATIN;

BIOASSAY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DISEASE COURSE; DISEASE MARKER; HEALTH CARE POLICY; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE CONTRACTION; HUMAN; OBESITY; PANCREAS CANCER; PATIENT SAFETY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP APNEA SYNDROME; SOMNOLENCE;

BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL; EVIDENCE-BASED MEDICINE; HEART DISEASES; HUMANS; INSTITUTE OF MEDICINE (U.S.); UNITED STATES; VENTRICULAR PREMATURE COMPLEXES;

EID: 80054744852     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/JCSM.1342     Document Type: Review

References (3)

1. Institute of Medicine Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease: Report on the Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. The National Academies Press, Washington, DC 2010.
2. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-12.
3. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.